William Harrell
Internal Medicine · Los Alamitos, CANPI 1083673685
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Lilly USA, LLC at 25.2% of the total. 2023 is the largest year on record at $606, 2.2 times the $270 reported in 2019.
Across 101 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$594
- AbbVie$295
- Novo Nordisk$249
- Mannkind Corporation$229
- Bayer$131
- Galderma Laboratories, L.p.$125
- plus $730 from 15 others
What the payments were for
- Food & beverage$2,353100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 24 | $594 |
| AbbVie(2 entities) | 14 | $295 |
| Novo Nordisk | 11 | $249 |
| Mannkind Corporation | 12 | $229 |
| Bayer | 5 | $131 |
| Galderma Laboratories, L.p. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 7 | $109 |
| Boehringer Ingelheim | 3 | $92 |
| IBSA Pharma Inc. | 4 | $89 |
| Dexcom, Inc. | 3 | $79 |
| Abbott | 3 | $66 |
| Medtronic | 2 | $49 |
| Ironshore Pharmaceuticals Inc. | 2 | $44 |
| Merck | 2 | $36 |
| Tolmar, Inc. | 2 | $36 |
| Johnson & Johnson | 1 | $28 |
| Halozyme Inc | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Novartis | 1 | $21 |
| AstraZeneca | 1 | $17 |
| Gilead | 1 | $17 |
How this compares
$2,353 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 12 | $15,235 |
| EliquisApixaban | 12 | $9,849 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $3,538 |
| SynthroidLevothyroxine Sodium | 24 | $1,629 |
| Rosuvastatin Calcium | 28 | $1,005 |
| Atorvastatin Calcium | 66 | $571 |
| Levothyroxine Sodium | 37 | $554 |
| Gabapentin | 25 | $516 |
| Amlodipine Besylate | 48 | $442 |
| Liothyronine Sodium | 11 | $393 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 15 | $298 |
| Tamsulosin Hcl | 12 | $290 |
| Metoprolol Succinate | 17 | $279 |
| Olmesartan Medoxomil | 14 | $271 |
| Potassium Chloride | 23 | $265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $17 | $15,23512 claims |
| AbbVieSynthroid | $295 | $1,62924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Alamitos
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.